Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 25452452

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2015 May 1
First author
Motzer RJ

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Motzer RJ
      type
      Author
    2. name
      Rini BI
      type
      Author
    3. name
      McDermott DF
      type
      Author
    4. name
      Redman BG
      type
      Author
    5. name
      Kuzel TM
      type
      Author
    6. name
      Harrison MR
      type
      Author
    7. name
      Vaishampayan UN
      type
      Author
    8. name
      Drabkin HA
      type
      Author
    9. name
      George S
      type
      Author
    10. name
      Logan TF
      type
      Author
    11. name
      Margolin KA
      type
      Author
    12. name
      Plimack ER
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Motzer RJ
      type
      Author
    2. name
      Rini BI
      type
      Author
    3. name
      McDermott DF
      type
      Author
    4. name
      Redman BG
      type
      Author
    5. name
      Kuzel TM
      type
      Author
    6. name
      Harrison MR
      type
      Author
    7. name
      Vaishampayan UN
      type
      Author
    8. name
      Drabkin HA
      type
      Author
    9. name
      George S
      type
      Author
    10. name
      Logan TF
      type
      Author
    11. name
      Margolin KA
      type
      Author
    12. name
      Plimack ER
      type
      Author
    bibliography ids
    1. nci-bib-0d3ccd3502c62b66284249ea
    book metadata
    content sha256
    777e26b524786fe76d841808a8bc150868b822125041a11cb2c4b9955b18e3ec
    document type
    citation
    dois
    1. 10.1200/JCO.2014.59.0703
    electronic publication date
    display
    2014 Dec 1
    precision
    day
    year
    2014
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:25452452
    immutable id
    pubmed:25452452@777e26b524786fe76d841808a8bc150868b822125041a11cb2c4b9955b18e3ec
    journal
    abbreviation
    J Clin Oncol
    issn electronic
    1527-7755
    issn print
    0732-183X
    issue
    13
    name
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    nlm unique id
    8309333
    pages
    1430-7
    volume
    33
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      25452452
      provenance
      batch id
      863b068fe5a07222af6a
      provider
      NCBI PubMed ESummary
      record sha256
      2c5806494c1d5b483d32640fe71e4747e873856c4ffca864184791f4bc123c0c
      response sha256
      80b1cc99e93fcfceb3e1b12ea433c615b032a2db13a615db7a6e9382c17c5034
      retrieved at
      2026-09-09T23:47:07.648963+00:00
      publication date
      display
      2015 May 1
      precision
      day
      year
      2015
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Multicenter Study
      4. Randomized Controlled Trial
      5. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/25452452/
      title
      Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

      Preserved source evidence · Not medical advice